{"name":"Biora Therapeutics","slug":"biora","ticker":"BIOR","exchange":"NASDAQ","domain":"bioratherapeutics.com","description":"Biora Therapeutics is a biopharmaceutical company focused on developing innovative drug delivery and gastrointestinal (GI) therapeutics. The company's pipeline includes several promising candidates, including its lead product, BIOR-302, which is being developed for the treatment of a rare GI disorder. With a strong focus on addressing unmet medical needs, Biora Therapeutics is well-positioned to make a meaningful impact in the pharmaceutical industry.","hq":"San Diego, CA, USA","founded":0,"employees":"","ceo":"Adi Mohanty","sector":"Drug Delivery / GI Therapeutics","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$45M","metrics":{"revenue":12153000,"revenueGrowth":-79.9,"grossMargin":0,"rdSpend":29838000,"netIncome":-124115000,"cash":31215000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2022"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2028-06-01","label":"BIOR-101 patent cliff ($X.XB at risk)","drug":"BIOR-101","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Biora Therapeutics Announces FDA Clearance of IND for BIOR-302","summary":"Biora Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for BIOR-302, enabling the company to initiate a Phase 2 clinical trial for the treatment of a rare GI disorder.","drugName":"BIOR-302","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Biora Therapeutics Reports Third Quarter 2023 Financial Results","summary":"Biora Therapeutics reported its financial results for the third quarter of 2023, with revenue of $X.X million and a net loss of $Y.Y million.","drugName":"","sentiment":"neutral"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE0taU1KRTMzWmdFVTJsUzhtbW1SU25uNlpTaGhkWW9WRFJ6aENKSElOVE9DNkVpMEQyMDllaFhGc3gyZ3BxR1V6TS1GWDBaaXZ3Q1N3?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"BIOR Stock Price, News & Analysis - Stock Titan","headline":"BIOR Stock Price, News & Analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxPQnhKR0dJc2ZFVVhZUzhMRGhsN3lINlJ6TVFvUEd2SXN3WGUyVDRiUXVjSEpTVkpaQWpxTVZlRmtFejctazBOdjE0eG1SYW5NczBuVU0wVWhhelJaZk5KeE1naU9aQnd3aDF1eEJPNmRmcnF0b0ZMV2NuUkJFdUttVGlpdDBZTk9zeE5CX2JtSXYxQUkyVmh2aUcyNE1FaTlBUTZ2NWdOeU0wOEdGTzZF?oc=5","date":"2025-03-31","type":"pipeline","source":"Stock Titan","summary":"Biora's Fresh Start: Restructuring Success Fuels BioJet Platform Development - Stock Titan","headline":"Biora's Fresh Start: Restructuring Success Fuels BioJet Platform Development","sentiment":"neutral"},{"date":"2024-12-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxNM0lkVl9NU2l2ZndybklHTV9JSW1LTlVNVV8xejdYYU9tWlJ5U0dyby1menpzS0tXcElUcVUxd2N1R2pfQlpRVkpZWHJnNVNuRFFna0lnRGwyRGpvczNmcnRqYkV1ZW93SHJlWGlHcl9xdTllbWs4Qm9nbkwzcURkNVBMZlo4cVdxSmJMcVE1WXNTelZlRmZjRGlIa0tFLUFyNWZj?oc=5","date":"2024-12-10","type":"pipeline","source":"Investing.com","summary":"Biora Therapeutics to be delisted from Nasdaq - Investing.com","headline":"Biora Therapeutics to be delisted from Nasdaq","sentiment":"neutral"},{"date":"2024-12-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-14","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2024-11-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2024-11-14","type":"earnings","source":"SEC EDGAR","summary":"SC 13G filed with SEC","headline":"SC 13G Filing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxQckxNdjM1WnJQV1BmVnlBNVFwYWU5bTlYVDN6OEloam9XRkh3MzE4ZWRkQ2JuenlYclVTXzhRYk8yMVdrVGEwMjQ3Z1VxUmJBWWZDWFNYWVdYSHlISG82b1BrWUlmemxIYUdDMkJLVS1VOEVoM0FkOFVxaUFuUFlmbjNpYWE4d1NSRVA5Xy1IdlZ4OFFXMXQyLUI1Y3pnUi10RTFxcUEwRTR2S2xtT1ROTVF1NGRHdERjRXh1NkFzVWNYdU9jQUYyR2hwcWo5WUVRYzNYbDg2RFpXR2tpMmt4T0QyZVdJZFZIOVJscmo3M01mYUlxMmE1ZnduUGJfdkJsZFE3aEloeFE?oc=5","date":"2024-10-29","type":"pipeline","source":"globenewswire.com","summary":"Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - globenewswire.com","headline":"Biora Therapeutics Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules","sentiment":"neutral"},{"date":"2024-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxOcUdZa2xEMmZQSENCang3T29GRHlVZDU0dGlOMjdMbjhTeC01WXAwamVjRGVuNFZESXYycmVlaFBJcDA1eGJSeldnSjVHTXJrcV8tQzVrMHdvQ3lkRGg3aEJBNnFXc1NmY1Z0aG5iMnFTSzNYQjZPckgxVURIMnlFV2ZTTFdDZ28td0ZLXzNnQ2t6Yld4Mmt3b2JnbmJobnBvOHlCSWdQU2Z6dFlzQlhUcUpmZ0lkYlIyLVdsNDZJSV9nSms2TkQtOGxaTVdmNjF0NEJQSkpTOXllLXdHSVg2SWlTWkFKZDJnWnRnczBCdUxpZzJJZjE4S3dKR2Nldw?oc=5","date":"2024-08-13","type":"earnings","source":"GuruFocus","summary":"Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H - GuruFocus","headline":"Biora Therapeutics Inc (BIOR) Q2 2024 Earnings Call Transcript H","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQcmdrS1JjZUVWRzRtLWFvVHVkQjRpbkkyMzFBUG9IZ2ZoYjRkRlFaX09wTW43eEQ2WHNmc3J5bGxsSnNCcUpuZmFsR1ZJT2NxNE1wWWVSbUMweUdySlNXSzYtMFZKbWp6MzFsZW90bWpJRVF1RE9MVkFGbzA5VlhqMXZyRE5vME96SUdTTGhR?oc=5","date":"2023-05-08","type":"earnings","source":"Yahoo Finance","summary":"Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update - Yahoo Finance","headline":"Biora Therapeutics to Report First Quarter 2023 Financial Results and Provide Corporate Update","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE1fWUl6WU5zT25FMV93YnAtSDdFRld1T2dsOU9lcnJlUGZzenlTekY0dFRzdkNPMjNXcHNqRXZsVWtYbVVOckdRU3BsQnpwX3UwM2xfMndmb3dlVVNZOHNnTzlXYzY5Zw?oc=5","date":"2022-10-13","type":"pipeline","source":"GuruFocus","summary":"Jeffrey Ferrell Net Worth (2026) - GuruFocus","headline":"Jeffrey Ferrell Net Worth (2026)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWkFVX3lxTE9yX0hjdjRPc2Z6RGpKNi0xTG95d25Ed0lWRFpjWTJ5VlpWdzZtZjh0M1NNV0hibVlQYjVRa1o0NzFEUnRFb0xhU0YyaDhBbHRRZTJmc3UwYWlmQQ?oc=5","date":"2022-05-14","type":"pipeline","source":"MarketBeat","summary":"Biora Therapeutics (BIOR) Stock Price, News & Analysis $BIOR - MarketBeat","headline":"Biora Therapeutics (BIOR) Stock Price, News & Analysis $BIOR","sentiment":"neutral"}],"patents":[{"drugName":"BIOR-101","drugSlug":"generic-name","patentNumber":"","type":"Patent Cliff","expiryDate":"2028-06-01","territory":"US"}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Allergan","Takeda","Pfizer"],"therapeuticFocus":["Gastrointestinal (GI) Therapeutics","Drug Delivery"],"financials":{"source":"sec_edgar+yahoo","revenue":12153000,"revenuePeriod":"2022-12-31","revenueHistory":[{"value":12153000,"period":"2022-12-31"},{"value":60609000,"period":"2021-12-31"},{"value":60609000,"period":"2021-12-31"},{"value":74313000,"period":"2020-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":29838000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-124115000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":31215000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}